Exhibit 99.1
COMPANY CONTACT:
Rhonda F. Rhyne, President
rrhyne@cardiodynamics.com
800-778-4825 Ext. 1013
CARDIODYNAMICS ANNOUNCES PREDICT STUDY PUBLICATION IN
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (JACC)
21 LEADING CENTERS DEMONSTRATE ICG AS POWERFUL PREDICTOR OF
HEART FAILURE OUTCOMES
SAN DIEGO--June 6, 2006-- CardioDynamics (Nasdaq: CDIC), the innovator and
leader of impedance cardiography (ICG) technology, today announced publication
of the Company's PREDICT (Prospective Evaluation and Identification of
Decompensation by ICG Test) study, demonstrating a significant relationship
between BioZ(R) ICG parameters and the occurrence of near-term major heart
failure events (emergency department visit, hospitalization, or death). The
results were published online in the Journal of the American College of
Cardiology (JACC), the leading cardiology journal and the official journal of
the American College of Cardiology (ACC). The study will also be published in
the June 2006 print version of the Journal and will be received by over 29,000
subscribers who are specialists in Cardiovascular and Internal Medicine,
Cardiovascular Surgery, Pediatric Cardiology, and General and Family
Practitioners.
The PREDICT study included investigators from 21 leading U.S. heart failure
centers. Researchers followed 212 heart failure patients in outpatient clinics
for a total of over 2,300 visits. Patients' BioZ ICG measurements were taken in
addition to standard baseline variables that included their age, sex, heart
failure cause, ejection fraction, medications, and standard clinical variables
that included patient self-assessment, vital signs, weight, and heart failure
functional classification (referred to as "New York Heart Association (NYHA)
class"). ICG parameters were considered as a single BioZ "ICG score" to assess
each patient as low, average, or high risk for a major heart failure event
within the following two weeks. Importantly, patient visits with a high-risk
BioZ ICG score were over eight times more likely to die or experience a heart
failure-related hospitalization or emergency room visit than those with a
low-risk BioZ ICG score. In addition, a high-risk BioZ ICG score was able to
predict a major heart failure event four times more often than the most powerful
single clinical variable (NYHA class IV). NYHA class IV includes heart failure
patients in which any physical activity creates discomfort, and symptoms occur
at rest.
Milton Packer, M.D., Chair, Department of Clinical Sciences at the University of
Texas Southwestern Medical Center in Dallas, was the principal investigator of
the PREDICT study and lead author on the paper. Dr. Packer is one of the leading
experts in the treatment of heart failure and has been instrumental in the
introduction of a number of new treatments. He is the author of more than 200
papers and serves on the editorial boards of numerous major medical journals.
Currently he is on the executive committee of both the American Heart
Association and the American College of Cardiology and is the past-President of
the Heart Failure Society of America. Dr. Packer is also a primary consultant to
the National Institutes of Health (NIH) and the Food and Drug Administration
(FDA) on the management of heart failure and on matters related to
cardiovascular research and drug development and health care policy.
Dr. Packer stated, "Physicians treating heart failure patients are in need of a
prognostic tool that helps them indicate which patient is at greatest risk for
death or hospitalization. The PREDICT results suggest that when performed at
regular intervals in stable patients with heart failure with a recent episode of
clinical decompensation, ICG can identify patients at increased near-term risk
of recurrent decompensation."
"The publication of PREDICT is a key milestone for CardioDynamics' ICG
acceptance within the medical community. The data from this study illustrate the
clinical importance of our technology in the treatment of heart failure," stated
Michael K. Perry, CardioDynamics' Chief Executive Officer. "There are nearly
five million Americans currently living with heart failure and 550,000 new cases
of heart failure diagnosed each year. As the older population increases over the
next few decades, so will the number of people living with heart failure. At
this time, heart failure can be managed but not cured - in fact, about
two-thirds of all patients die within five years of diagnosis. We will continue
to work with the research and clinical communities to demonstrate how our
patented technology can aid physicians in the early detection and improved
treatment of this deadly disease."
THE FULL LIST OF AUTHORS ON THE PREDICT PUBLICATION INCLUDES:
Milton Packer, MD, FACC, University of Texas Southwestern Medical Center,
Dallas, TX
William T. Abraham, MD, FACC, Ohio State University Heart Center,
Columbus, OH
Mandeep R. Mehra, MD, FACC, University of Maryland School of Medicine,
Baltimore, MD
Clyde W. Yancy, MD, FACC, University of Texas Southwestern Medical Center,
Dallas, TX
Christine E. Lawless, MD, FACC, DuPage Medical Group, Chicago, IL
Judith E. Mitchell, MD, FACC, SUNY Downstate Medical Center, New York, NY
Frank W. Smart, MD, FACC, Texas Heart Institute at St. Luke's Episcopal
Hospital, Houston, TX
Rachel Bijou, MD, FACC, Columbia-Presbyterian Medical Center, New York, NY
Christopher M. O'Connor, MD, FACC, Duke University Medical Center, Durham, NC
Barry M. Massie, MD, FACC, San Francisco VA Medical Center, San Francisco, CA
Ileana L. Pina, MD, FACC, Case Western Reserve University, Cleveland, OH
Barry H. Greenberg, MD, FACC, University of California, San Diego, San Diego, CA
James B. Young, MD, FACC, Cleveland Clinic Foundation, Cleveland, OH
Daniel P. Fishbein, MD, FACC, University of Washington, Seattle, WA
Paul J. Hauptman, MD, FACC, St. Louis University, St. Louis, MO
Robert C. Bourge, MD, FACC, University of Alabama, Birmingham, AL
John E. Strobeck, MD, PhD, FACC, Heart Lung Associates of America, Hawthorne, NJ
Srinvivas Murali, MD, FACC, University of Pittsburgh Medical Center, Pittsburgh,
PA
Douglas Schocken, MD, FACC, University of South Florida, Tampa, FL
John R. Teerlink, MD, FACC, San Francisco VA Medical Center, San Francisco, CA
Wayne C. Levy, MD, FACC, University of Washington, Seattle, WA
Robin J. Trupp, MSN, RN, Ohio State University Heart Center, Columbus, OH
Marc A. Silver, MD, FACC, Advocate Christ Medical Center, Chicago, IL
TO OBTAIN COPIES OF THE PREDICT PUBLICATION, PLEASE CONTACT RHONDA RHYNE AT
rrhyne@cdic.com.
ABOUT CARDIODYNAMICS:
CardioDynamics (Nasdaq: CDIC), the ICG Company, is the innovator and leader of
an important medical technology called impedance cardiography (ICG). The Company
develops, manufactures and markets noninvasive ICG products and medical device
electrodes. The Company's ICG Systems are being used by physicians around the
world to help battle the number one killer of men and women--cardiovascular
disease. Partners include GE Healthcare and Philips Medical Systems. For
additional information, please refer to the company's Web site at www.cdic.com.
FORWARD-LOOKING (SAFE HARBOR) STATEMENT:
Except for historical and factual information contained herein, this press
release contains forward-looking statements, such as clinical data results,
publication of and future clinical trials, the accuracy of which is necessarily
subject to uncertainties and risks including the Company's primary dependence on
the BioZ product line, and various uncertainties characteristic of early growth
companies, as well as other risks detailed in the Company's filings with the
SEC, including its 2005 Form 10-K. The Company does not undertake to update the
disclosures contained in this press release.